Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 3/20 | 0.42 |
| ▸ | JAK3 | P52333 | 2/20 | 0.42 |
| ▸ | EGFR | P00533 | 2/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.40 |
| ▸ | DYRK3 | O43781 | 2/20 | 0.40 |
| ▸ | CDK1 | P06493 | 2/20 | 0.40 |
| ▸ | ROS1 | P08922 | 2/20 | 0.40 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.40 |
| ▸ | CDK2 | P24941 | 2/20 | 0.40 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.40 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.40 |
| ▸ | CLK2 | P49760 | 2/20 | 0.40 |
| ▸ | IRAK1 | P51617 | 2/20 | 0.40 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.40 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.40 |
| ▸ | SLK | Q9H2G2 | 2/20 | 0.40 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.40 |
| ▸ | CDC7 | O00311 | 1/20 | 0.40 |
| ▸ | PLK4 | O00444 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20553506 | 0.85 | MAP4K4 (0.52) | JAK2JAK3EGFRMAP4K4SRC | |
| SCHEMBL30406029 | 0.82 | MAPT (0.37) | JAK2JAK3EGFRMAP4K4DYRK3 | |
| SCHEMBL23150477 | 0.76 | MTOR (0.54) | PIK3CD | |
| SCHEMBL20445971 | 0.75 | KMO (0.44) | MAP4K4KDRLIMK1LOXL2KMO | |
| SCHEMBL30405599 | 0.73 | SRC (0.42) | JAK2JAK3EGFRMAP4K4DYRK3 | |
| SCHEMBL20553262 | 0.73 | SRC (0.42) | JAK2JAK3EGFRMAP4K4DYRK3 | |
| SCHEMBL5802174 | 0.72 | JAK2 (0.67) | JAK2JAK3EGFRMAP4K4DYRK3 | |
| SCHEMBL27586600 | 0.71 | JAK2 (0.42) | JAK2JAK3EGFRMAP4K4DYRK3 | |
| SCHEMBL15648870 | 0.71 | SRC (0.65) | JAK2JAK3EGFRMAP4K4DYRK3 | |
| SCHEMBL23150464 | 0.70 | JAK3 (0.59) | JAK2JAK3EGFRMAP4K4DYRK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4168002-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2023-04-26 | — | — | EP | disclosed |
| WO-2021257736-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2021-12-23 | — | — | WO | disclosed |
| US-20210094975-A1 | RAPAMYCIN ANALOGS AS MTOR INHIBITORS | Revolution Medicines, Inc. | 2021-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210094975-A1 | RAPAMYCIN ANALOGS AS MTOR INHIBITORS | MTOR, RICTOR, RPTOR | JAK2 445/4885JAK3 2053/4885EGFR 852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.